To the Editor-Despite increases in obesity, data to guide dosing of voriconazole in this population are lacking. We describe the dosing of intravenous voriconazole in an obese patient undergoing an allogeneic hematopoeitic cell transplant.
A 30-year-old male underwent a matched unrelated donor allogeneic stem cell transplant (SCT) for the treatment of acute promyelocytic leukemia. On day 11 following SCT, the patient spiked a neutropenic fever and was initiated on vancomycin and meropenem. The patient continued to spike fevers and subsequently received treatment with micafungin. Despite the broad spectrum antimicrobial coverage, the patient continued to spike fevers, and empiric mold coverage with voriconazole was initiated on day 18. The patient weighed 225 kg and had a body mass index of 84.5 kg/m 2 . Due to lack of data regarding dosing of voriconazole in obese patients, the decision was made to dose voriconazole based on an adjusted body weight ([actual weight-ideal weight] 0.4 1 ideal weight). The patient received a loading dose of voriconazole 6 mg/kg based on adjusted body weight PO every 12 hours for 2 doses, followed by voriconazole 4 mg/kg every 12 hours. Levels were drawn at 1 hour, 5 hours, 9 hours and 12 hours after the 8th dose of voriconazole to estimate the area under the curve (AUC) and correlate with previously described pharmacokinetics in the allogeneic transplant population [1] . Little correlation with weight-based dosing using total body weight, lean body weight, adjusted body weight, or body surface area was seen [2] . Based on our findings, it appears an adjusted weight based dosing for obese allogeneic transplant patients will yield a voriconazole AUC similar to a nonobese population. However, considering the nonlinear pharmacokinetics of voriconazole, further studies are warranted to determine ideal voriconazole dosing in this patient population.
